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The reversible reaction of cyclohexane-1,2-dione with the 
guanidino function of Arg-B22 in bovine insulin gave the dihy-
droxycyclohexylene [DHCH]-Arg-B22-insulin complex (I) which, 
after selective tryptic cleavage at the Lys-B29 residue and rege-
neration of the guanidino group, afforded bovine des-AlaB30-
-insulin (III) in an overal 85.80/o yield. The truncated insulin III 
was converted into the regular zinc salt and, under conditions 
that favour binding of more than 2 Zn atoms per insulin hexamer 
unit, into a crystalline suspension. When tested for their hypogly-
caemic activity, the two forms of III exhibited significantly diffe-
rent durations of the effect in mice: the blood glucose curves 
obtained for the III-Zn salt and the III-crystalline suspension 
were indistinguishable from those exerted by regular- and long-
-acting bovine zinc insulin, respectively. 
INTRODUCTION 
In a previous paper\ we have shown that cyclohexane-1,2-dione, the 
bifunctional reagent used by Patthy and Smith2- 4 in a reversible modification 
of the arginyl residues in proteins, reacts specifically and completely with the 
guanidino function of the arginyl-B22 residue in porcine insulin to give the 
N 7,N8-(1 ;2-dihydroxycyclohex-1,2-ylene)-arginine-borate insulin complex ([DH-
CH-Arg-B22] -insulin) which, upon treatment with hydroxylamine, regenerates 
insulin of unchanged biological acticity. Incubation of the complex with trypsin 
led to selective cleavage at the Lys-B29 residue to give, after removal of the 
DHCH group, porcine des-AlaB30~insulin in high yield.1 lVIorihara et al.5 
claimed that des-Ala-B30-insulin, obtained6 by incubation of insulin with 
carboxypeptidase A, reacted with cyclohexane-1,2-dione to produce des-Ala-
-B30-[DHCH-Arg-B22]-insulin; the latter was converted by trypsin-catalyzed 
coupling into semi.synthetic human insulin. In a study on the role of the 
Arg-B22 residue in insulin action, Rose et al.7 prepared porcine [DHCH-Arg-
-B22]-insulin complex and examined its ability to lower blood sugar concen-
tration. 
In the presence of zinc ions, depending on the ionic strength and the 
nature of anions present in the solution, insulin gives two crystalline forms 
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which contain per insulin hexameric8 unit 2 and 4 z~nc atoms, respectively; 
crystallographic studies have established9•10 that the C-terminal Ala-B30 is 
not included into regions of the hexamer packed helices. The effect of added 
zinc ions in the timing of insulin hypoglycaemic action has been investigated 
in detail, and preparations possessing a low solubility in tissue fluids and a 
prolonged duration of action have been introduced into insulin therapy8. 
Studies from several laboratories have shown that the Ala-B30 residue of 
insulin is not essential for bi·o1ogical activity of the molecule6•11- 13. 
In view of the above findings it was of interest to synthesize bovine 
des-Ala-B30-insulin, to examine its ability to bind zinc under different expe-
rimental conditions, and to fi:nd out whether the products formed exhibit some 
different physical and biological properties. 
RESULTS AND DISCUSSION 
The reaction of cyclohexane-1,2-dione with the arginyl-B22 residue of 
bovine insulin to give the [DHCH-Arg-B22]-insulin complex (I) proceeded 
smoothly when either the Zn-free form or the 2Zn crystals were used as the 
starting material. However, bovine zinc insulin required a considerably higher 
propor tion of pH = 9 buffer to attain dissolution than did the corresponding 
porcine insulin salt. Therefore, in order to avoid concentraHons of large volumes 
of the solvent, we used the more soluble Zn-free form in preparative-scale 
experiments. 
Variation of the reaction conditrons previously employed1 in the synthesis 
of porcine des-Ala-B30-i<nsulin led to simplification and improvement of the 
whole procedure. The most notable changes were: (a) a decrease in reaction 
time required for the formation of the complex I (from 12 to 3 hr) , (b) a 
decrease in the trypsin incubation-time needed for quantitative cleavage of 
the LysB29-AlaB30 peptide bond in I (from 20 to 8 hr), and (c) the use of 
even milder conditions for the removal of the DHCH group from I and des-
-AlaB30-[DHCH-ArgB22]-insulin (II) (0.1 M NH20H at room temperature, 
instead of 0.5 M NH20H at 37 °q. 
The homogeneity of the DHCH-complex I was established by amino acid 
analysis (Table I) and electrophoresis; treatment of a sample with hydroxy-
lamine regenerated bovine insulin of the original activity (mouse fall test). 
Trypsin digestion of I gave the des-Ala-B30-insulin complex II (Table I) which, 
after deblocking and chromatography of the product on a Sephadex G-50 
column (fine), afforded bovine des-AlaB30-insulin (III, Table I) in an overall 
85.80/o yield, calculated on the starting Zn-free bovine insulin. The biological 
activity of III was equipotent to that of the parent insulin (mouse fall test). 
Conversion of the truncated insulin III into the 2Zn form was effected 
by the standard procedure14 used in the preparations of regular insulin zinc 
salts. Treatment of III under conditions that favour binding of more than two 
zinc atoms per hexamer unit was carried out by following essentially the 
sodium chloride-sodium acetate crystallisation method elaborated by Schlicht-
krull8. Compound III behaved rather similarly to the identically treated bovine 
insulin and deposited at pH = 7.4 a crystalline suspension of rhombohedral 
crystals (10-40 ~tm diameter). The zinc content (2.170/o w /w) of these crystals 
indicated the presence of additionally bound zinc atoms per unit cell. 
The blood sugar-lowering activity of the two types of bovine des-Ala-
-B30- insulin zinc crystals was tested on alloxan-induced diabetic mice and 
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TABLE I 
Amino Acid Ratios of Bovine [DHCH-Arg-B22] - insulin Complex (I), Des-Ala-B30-
-insulin Complex II, and Bovine Des -Ala-B30-insulin (III)" 
Amino Acid Found: 
Residue" I II III 
Asp (3) 3.00 3.00 3.ooc 
Thr (1) 0.97 0.89 1.11 
Ser (3) 2.78 2.83 2.99 
Glu (7) 7.11 7.04 7.04 
Pro (1) 0.93 1.02 1.01 
Gly (4) 4.02 4.01 4.03 
Ala (3) 2.94 1.97 1.90 
Cys (6) 4.27 4.37 4.13 
Val (5) 3.78 3.79 3.60 
Ile (1) 0.19 0.21 0.17 
Leu (6) 5.97 6.02 5.92 
Tyr (4) 3.83 3.89 3.75 
Phe (3) 2.94 2.93 2.87 
His (2) 2.01 2.03 2.01 
Lys (1) 0.99 0.97 0.9G 
Arg (1) 0.00 0.00 1.00 
' Ratios a r e calculated with respect to Asp = 3.00, and the values are not corrected for 
destruction. Hydrolysis of samples was performed in 6 M HCl and in the presence of thio-
glycolic acid, if not stated otherwise. " The values in brackets refer to the number of amino 
acid residues in bovine insulin. c Hydrolysis performed without addition of thioglycolic acid. 
compared in parallel experiments with the effects given by regular bovine 
zinc insulin and the long-acting insulin Novo Ultralente. As can be seen from 
Figure 1., the blood glucose curves exhibited by the standardly prepared 
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Figure 1. A comparison of the blood glucose response following the administration of: bovine 
des-Ala-B30-insuiin (III)-zinc salt 0---0 ; bovine insulin zinc salt (PLIV A) X---X ; 
bovine des-Ala-B30-insulin (III) -crystalline suspension •---•; insulin Novo Ultralente 
• - --•. Insulins were administered subcutaneously to alloxan-diabetic mice in doses of 
4 I. U. per mouse; the values represent the mean response of 10 mice in each group. 
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insulin preparations. On the other hand, the glucose curve observed after inje-
ction of the III-crystalline suspension differed substantially from the curves 
given b y the two former preparations and paralleled that exhibited by the 
insulin Novo Ultralente, at least for the times investigated. · 
From the present investigatron, it can b e concluded that r emoval of the 
C-terminal alanine resid ue from bovine insulin does not affect the ability of 
the molecule to exhibit two t ypes of zinc binding. Moreover, conditions used 
for conversion of the intact molecule into insulin preparation with prolonged 
action showed to be also valid for the formation of a high-zinc des-Ala-B30-
-insulin crystalline suspension ·of very low solubility. The fact that the latter 
preparation exhibited a remarkably long duration of blood sugar-lowering 
effect in mice can be considered as additional evidence for the C-terminal 
alanine not being essential to ·insulin hypogly caemic activity. 
EXPERIMENTAL 
Materials 
Bovine insulin, crystalline zinc salt, was obtained from PLIVA (lot No. 1,431,124, 
24.4 I.U./mg) and was used throughout. Bovine zinc-free insulin was prepared after 
Sluyterman15 as already described16 for porcine insulin. Insulin Novo Ultralente was 
from Novo, Denmark. Cyclohexane- 1,2-dione and trypsin (bovine, Type XI, chymo-
trypsin free) were from Sigma, hydroxylamine hydrochloride p. a. from Merck, and 
thioglycolic acid from Fluka. Other chemicals were high-purity preparations from 
commercial sources. 
Methods 
All separations on columns were carried out at 4 °C. Products were recovered 
by evaporation of the eluates (by concentration, rotary evaporator) in a bath temp. 
30-33 °c, followed by lyophilisation . 
Electrophoresis on cellulose acetate was performed on strips (2.5 x 14 cm) in a 
standard Chemetron apparatus at 200 V at pH 4.8 (0.1 M pyridine/6 M urea buffer 
adjusted with acetic acid), and at pH 8.0 (0.065 M phosphate/7 M urea buffer adjusted 
with acetic acid). The strips were stained with a 0.25°/o solution of Ponceau S in 3°/0 
trichloroacetic acid. Disc-gel electrophoresis was carried out on acrylamide gel at 
pH 9.5 (0.05 M Tris/0.03 M glycine); the bands were stained with Coomassie Brilliant 
Blue R- 250 (Sigma) . 
Amino acid analyses were made on a Biotronik LC 2000 automatic amino acid 
analyzer. Hydrolyses were performed in 6 M HCl in the presence (20 ~lmol) and 
absence of thioglycolic acid, in sealed tubes at 110 °c for 14 hr. Zinc determinatiori 
was carried out by atomic absorption spectroscopy. 
Bov ine [DHCH-Arg-B22]-insulin (I) 
Bovine zinc-free insulin (200 mg, 35 ~lmOl), dissolved in 0.2 M sodium borate 
buffer, pH = 9.0 (30 ml), was preincubated at 37 °c for 1 hr whereupon cyclohexane-
- 1,2-dione (201.6 mg, 1.8 mmol) in the same buffer (6 ml) was added under a slow 
stream of nitrogen and the reaction was allowed to proceed for 3 hr. After cooling 
(ice-bath) and addition of 15°/o acetic acid to pH = 3, the solution was concentrated 
and chromatographed on a Sephadex G-50 (fine) column (2.5 X 90 cm) with 1 M 
acetic acid. Lyophilisation of the peak tubes (monitoring by absorption at 280 nm) 
gave 187 mg (91.00/o) of the complex I which amino acid analysis showed to be free 
of the starting insulin. 
In the same treatment of bovine zinc insulin (50 mg, 8.7 µmol), 18 ml of the 
buffer was required for dissolution; the isolated I (52 mg) was identical to the product 
obtained from zinc-free insulin. 
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Bovine Des-Ala-B30-[DHCH-Arg-B22]-insulin (II ) 
A solution of freshly prepared complex I (180 mg, 31 ~Lmol) in 0.1 M sodium 
borate buffer, containing 10 mmol CaC12, pH = 8.0 was incubated w ith trypsin (3.6 
mg in 6.0 ml of the same buffer) in two equal portions at 37 °c; after the third 
hour of incubation, the second half of the enzyme solution was added (final ratio 
E: S = 1 : 50), and the digestion was allowed to process for an additional 8 hr. After 
cooling (ice-bath) and acidification (150/o AcOH) to pH = 3, the digest was concen-
trated a nd fractionated on a Sephadex G-50 (fine) column (2.5 x 90 cm) with 1 M 
acetic acid. Lyophilisation of the main peak fractions gave II (170 mg, 95.60/o) as a 
flu ffy mass which was characterised by amino acid analysis. 
Bovine Des-Ala-B30-insulin (III ) 
The complex II (170 mg, 29.8 ~Lmol) was dissolved in 0.1 M hydroxylamine 
(34 ml), and the solution, adjusted with 0.1 M sodium h ydroxide to pH = 7.0, was 
kept under a slow stream of nitrogen at room temperature overnight. After addition 
of 150/o acetic acid to pH = 3, the solution was concentrated and chromatographed 
on a Sephadex G -50 (fine) column (2.5 X 90 cm) with 1 M acetic acid. L yophilisation 
of the peak tubes gave 168 mg, 800/o of III as a fluffy mass w hich was characterised 
by amino acid analysis. 
A sample of III (15 mg) was converted into the 2 Zn salt by the procedure 
given by P etersen. 14 
Regen eration of Bovine Insulin From the Complex I 
Treatm ent of a sample (5 mg) of I with 0.1 M h ydroxylamine (1 ml) as already 
described, yielded 4.5 mg (900/o) of bovine insulin w h ose electrophoretic mobility and 
biological activity (mouse fa ll test) were indistinguishable from those of the untreated 
bovine insulin . 
Preparation of Bovine Des-Ala-B30-insulin Crystalline Zinc Suspension 
Bovine des- Ala- B30-insulin (III, 120 mg) was dissolved in 0.015 M HCl (5.6 ml), 
and to the solution were added ZnCh (2.5 mg, quantity equivalent to a total of 10/o 
zn2+ by weight of III) and 0.4 M sodium acetate, containing 280/o NaCl and 0.40/o 
methyl p -hydroxybenzoate, pH = 10 (1.9 ml). The turbid solution was adjusted to 
pH = 5.75, and the crystallisation medium was stirred at room temperature for 24 
hr. The resulting crystalline suspension was diluted with 0.10/o aq. solution (w/w) 
of methyl p -hydroxybenzoate (65 ml), and a second portion of ZnCl2 (10 mg, quantity 
equivalent to 40/o of Zn2+ by weight of III) was then added. The final preparation 
was obtained by addition of 0.10/o solution of methyl p -hydroxybenzoate, with simul-
taneous adjustment of pH with 0.1 M NaOH, to make the volume up to 75 ml and 
the pH = 7.4; this preparation contained 40 I. U. of insulin/ml. The filtered crystals, 
dried in a vacuum desiccator to constant weight, contained 2. 17°/o of Zn. 
Biological Assays 
Biological activity of insulins and derivatives was tested either by the mouse 
fall test, or by using in vivo b lood glucose assay on alloxan diabetic mice17• Tetra-
h ydric alloxan in saline (0.50/o solution) was administered to mice intravenously (75 
or 100 mg/kg) a t least 2 days before subcutaneou s injection of 4 I. U./mouse (groups 
of 10) of insulin preparations18• Blood samples were taken before, 1, 6, 14 and 19 
hr after the injection, and glucose analyses were performed by th e glucose oxidase/4-
-aminophenazone method19• 
Acknowledgement. - We are indebted to Dr. M. Slijepcevic and Dr. M. 
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SAZETAK 
Kristalna suspenzija govedeg cink des-Ala-B30-insulina sa produzenom 
hipoglikemickom aktivnoscu 
B. MuLac-Jericev'ic, B. Vranesic* , S. Kveder, B. Jamnicky* i D. Kaglevic 
Reverzibilna r eakcija cikloheksan-1.2-diona i guanidino grupe A rg-B22 ostatka 
govedeg insulina dala je kompleks I koji j e nakon inku bacije sa tripsinom te rege-
neracije guanidino grupe dao govedi des-Ala - B30- insulin kao jedini produkt. Poka-
zano je da se ovakova »osakacena « molekula insulin a moze lako prevesti u regularnu 
2 Zn sol, a da pod uvjetima koj i pogoduju vezanju dodatnih atoma cinka daje suspen-
ziju kristala (sa drfaj 2.17°/o cinka) kao i nativni govedi insulin. Ispitivanja hipogli-
kemicke aktivnosti ovih dviju preparacija u miseva pokazala su da je trajanje 
hipoglikemickog efekta des-Ala-B30- insulin 2 Zn soli jednako onome nativnog gove-
deg insulina, dok je efekt kristalne suspenzij e des- Ala- B30-insulina mnogo duzi i 
jednak onome koji izaziva insulin produzenog djelovanj a (Ultralente). 
